26 completed, 4 terminated, 2 not yet recruiting, 2 unknown. 18 Phase 3, 7 Phase 2, 5 Not applicable, 5 Phase 4, 1 Phase 1.
Follow Chronic Idiopathic Constipation: new trials by email Literature Review of Chronic Idiopathic Constipation trials Research Report on Chronic Idiopathic Constipation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| "Efficacy and Safety of Linaclotide in Chronic Constipation" Linaclotide 72 micrograms, Linaclotide 145 micrograms, Placebo - Chronic Idiopathic Constipation, Irritable Bowel Syndrome (IBS-C) | Phase 4 | Not yet recruiting | Md Mehedi Shahriar | 90 | 2026-02-20 | 2026-02-25 |
| This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of IN-114199 in Healthy Participants IN-114199 2.5mg or placebo, IN-114199 10mg or placebo, IN-114199 20mg or placebo - Chronic Idiopathic Constipation | Phase 1 | Not yet recruiting | HK inno.N Corporation | 80 | 2024-12-16 | 2024-12-17 |
| Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic Constipation Linaclotide, LINZESS®, Placebo - Chronic Idiopathic Constipation | Phase 3 | Unknown | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 750 | 2021-03-05 | 2021-03-18 |
| Efficacy and Safety of Vibrant Capsule vs. Placebo for the Treatment of Chronic Idiopathic Constipation Vibrating capsule - Chronic Idiopathic Constipation | Not applicable | Completed | Vibrant Ltd. | 349 | 2019-04-08 | 2024-08-09 |
| Efficacy and Safety of Vibrant Capsule vs. Vibrant Placebo for the Treatment of Chronic Idiopathic Constipation (CIC) Vibrant capsule, Placebo - Chronic Idiopathic Constipation | Phase 4 | Completed | Vibrant Ltd. | 59 | 2018-07-26 | 2024-06-14 |
| A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE® Plecanatide - Chronic Idiopathic Constipation | Completed | Bausch Health Americas, Inc. | 7 | 2018-06-21 | 2019-11-22 | |
| Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo Lubiprostone, Placebo - Chronic Idiopathic Constipation | Phase 3 | Completed | Sucampo Pharma Americas, LLC | 552 | 2017-03-13 | 2020-01-14 |
| The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation CSP01, Carboxymethylcellulose (CMC), Placebo - Constipation, Chronic Idiopathic Constipation | Not applicable | Completed | Massachusetts General Hospital | 52 | 2017-03-07 | 2019-08-20 |
| An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation Plecanatide, Matching placebo - Chronic Idiopathic Constipation | Phase 2 | Completed | Bausch Health Americas, Inc. | 124 | 2017-01-01 | 2019-10-04 |
| An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults BLI400 Laxative - Constipation, Chronic Idiopathic Constipation | Phase 3 | Completed | Braintree Laboratories | 330 | 2016-06-01 | 2020-07-09 |
| BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults BLI400 Laxative, BLI400 Placebo - Constipation, Chronic Idiopathic Constipation | Phase 3 | Completed | Braintree Laboratories | 1020 | 2016-06-01 | 2020-07-27 |
| Lubiprostone for Treatment of Chronic Idiopathic Constipation Placebo, Lubiprostone - Chronic Idiopathic Constipation | Phase 3 | Completed | Takeda | 156 | 2016-04-14 | 2018-12-31 |
| An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation Linaclotide - Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation | Phase 4 | Completed | Forest Laboratories | 828 | 2015-11-01 | 2019-08-22 |
| A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults BLI400 Laxative, Lubiprostone - Chronic Idiopathic Constipation | Phase 3 | Completed | Braintree Laboratories | 459 | 2015-05-01 | 2020-07-27 |
| Elobixibat Colonic Motor Function Study elobixibat, placebo - Chronic Idiopathic Constipation | Phase 2 | Withdrawn | Ferring Pharmaceuticals | 2015-04-01 | 2015-06-03 | |
| Trial of Linaclotide in Patients With Chronic Idiopathic Constipation Linaclotide, Matching Placebo - Chronic Idiopathic Constipation | Phase 3 | Completed | Ironwood Pharmaceuticals, Inc. | 1223 | 2014-10-01 | 2017-06-15 |
| Botulinum Toxin Injection Versus Anal Myectomy in Management of Idiopathic Constipation Botulinum Toxin, Anal Myectomy - Chronic Idiopathic Constipation, Functional Constipation | Phase 4 | Unknown | Cairo University | 40 | 2014-09-01 | 2018-01-30 |
| Efficacy of Linaclotide to Senna for CIC Senna, Linzess - Chronic Idiopathic Constipation | Not applicable | Terminated | TriHealth Inc. | 9 | 2014-09-01 | 2019-07-02 |
| Performance, Efficacy and Safety of Vibrating Capsule in Aiding Constipated Individuals vibrating capsule, sham non-vibrating capsule - Chronic Idiopathic Constipation | Not applicable | Completed | Vibrant Ltd. | 144 | 2014-07-01 | 2017-11-07 |
| 12-Week Study of Plecanatide for CIC (The National CIC3 Study) Plecanatide, Placebo - Chronic Idiopathic Constipation | Phase 3 | Completed | Bausch Health Americas, Inc. | 1410 | 2014-04-01 | 2019-05-28 |
Showing 20 of 36. Sign in to see all of them.
Constipation (13) · Irritable Bowel Syndrome (2) · Bronchiolitis Obliterans Syndrome (1) · Dyspepsia (1) · Esophagitis (1) · Gastroesophageal Reflux (1) · Gastrointestinal Diseases (1) · Gastroparesis (1) · Nausea (1) · Vomiting (1)
Pathological Conditions, Signs and Symptoms (14) · Signs and Symptoms (14) · Signs and Symptoms, Digestive (14) · Digestive System Diseases (4) · Gastrointestinal Diseases (3) · Colonic Diseases (2) · Colonic Diseases, Functional (2) · Intestinal Diseases (2) · Bronchial Diseases (1) · Bronchiolitis (1) · Bronchiolitis Obliterans (1) · Bronchitis (1) · Deglutition Disorders (1) · Esophageal Diseases (1) · Esophageal Motility Disorders (1)
Lubiprostone (8) · plecanatide (7) · elobixibat (4) · linaclotide (4) · Bisacodyl (1) · Botulinum Toxins (1) · Botulinum Toxins, Type A (1) · Domperidone (1) · Equipment and Supplies (1) · Sennosides (1) · carbamic acid 3-(4-((4-amino-5-chloro-2-methoxybenzoylamino)methyl)piperidin-1-yl)-1-(4-fluorophenyl)propyl ester (1) · tegaserod (1)
Bausch Health Americas, Inc. (7) · Ferring Pharmaceuticals (4) · Braintree Laboratories (3) · Vibrant Ltd. (3) · Anchen Pharmaceuticals, Inc (1) · Cairo University (1) · Carle Physician Group (1) · Dartmouth-Hitchcock Medical Center (1) · Dr. Reddy's Laboratories Limited (1) · Forest Laboratories (1) · HK inno.N Corporation (1) · Ironwood Pharmaceuticals, Inc. (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Kissei Pharmaceutical Co., Ltd. (1) · Mallinckrodt (1)
United States (29) · Canada (5) · Czechia (3) · Poland (3) · South Africa (3) · United Kingdom (3) · Belgium (2) · Brazil (2) · Germany (2) · Hungary (2) · Israel (2) · Slovakia (2) · South Korea (2) · Sweden (2) · Bangladesh (1)
John McGowan (2) · Mary Beth Layton (2) · Andrew Batey, M.D. (1) · Anhthu Nguyen (1) · Anna Keck, PhD (1) · Ashis Patnaik, M.D (1) · Bernard J Lavins, MD (1) · Eugene Greenberg, MD (1) · Gary S Jacob, Ph.D. (1) · Irene Sarosiek, MD (1) · James Dougherty, MD (1) · John McGowan, MPH (1) · Kyle Staller, MD, MPH (1)
PMID 32660770, PMID 35086735, PMID 37332239, PMID 27650225, PMID 28169285, PMID 29147135, PMID 29343131, PMID 32449277, PMID 33834354, PMID 36822371, PMID 37162147